ECSP034420A - USE OF PARAPOXVIRUS OVIS VAPES AGAINST ORGAN FIBROSIS - Google Patents

USE OF PARAPOXVIRUS OVIS VAPES AGAINST ORGAN FIBROSIS

Info

Publication number
ECSP034420A
ECSP034420A EC2003004420A ECSP034420A ECSP034420A EC SP034420 A ECSP034420 A EC SP034420A EC 2003004420 A EC2003004420 A EC 2003004420A EC SP034420 A ECSP034420 A EC SP034420A EC SP034420 A ECSP034420 A EC SP034420A
Authority
EC
Ecuador
Prior art keywords
vapes
organ fibrosis
fibrosis
parapoxvirus ovis
against organ
Prior art date
Application number
EC2003004420A
Other languages
Spanish (es)
Inventor
Andreas Knorr
Dietrich Claudia Hirth
Olaf Weber
Gudrun Theiss
Angela Siegling
Tobias Schlapp
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of ECSP034420A publication Critical patent/ECSP034420A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24261—Methods of inactivation or attenuation
    • C12N2710/24264—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Addiction (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

PROBLEM TO BE SOLVED: To provide a medicament having a preventive or curative effect on organ fibrosis in humans.SOLUTION: The medicament shows the effect to a common final path to all diseases connected to fibrosis, using the fact that a preparation of parapoxviruses, obtained from the strains D 1701, orf-11, Greek orf strain 176, Greek orf strain 155, and the New Zealand (NZ) strains inhibit transformation of hepatic stellate cells into collagen producing-myofibroblast type.
EC2003004420A 2000-07-11 2003-01-10 USE OF PARAPOXVIRUS OVIS VAPES AGAINST ORGAN FIBROSIS ECSP034420A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10033581 2000-07-11

Publications (1)

Publication Number Publication Date
ECSP034420A true ECSP034420A (en) 2003-03-10

Family

ID=7648485

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004420A ECSP034420A (en) 2000-07-11 2003-01-10 USE OF PARAPOXVIRUS OVIS VAPES AGAINST ORGAN FIBROSIS

Country Status (14)

Country Link
JP (2) JP5587950B2 (en)
KR (1) KR100845643B1 (en)
CN (1) CN101444539B (en)
AT (1) ATE445413T1 (en)
BR (1) BRPI0112411B8 (en)
DE (2) DE10122233A1 (en)
DK (1) DK1303302T3 (en)
DO (1) DOP2001000210A (en)
EC (1) ECSP034420A (en)
ES (1) ES2332355T3 (en)
PE (1) PE20020218A1 (en)
PT (1) PT1303302E (en)
SV (1) SV2002000527A (en)
ZA (1) ZA200300276B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102015111756A1 (en) * 2015-07-20 2017-01-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Recombinant Orf virus vector
CA3018307A1 (en) 2016-02-16 2017-08-24 Osaka University Pharmaceutical composition for use in treating fibrosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4405841C1 (en) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotent non-specific immunity inducers based on combinations of poxvirus components, processes for their preparation and their use as pharmaceuticals
ES2125846T3 (en) * 1996-04-15 2001-12-16 Anton Prof Dr Med Vet Dr Mayr NEW INDICATIONS FOR THE USE OF MULTIPOTENT PARINMUNITY INDUCTORS FROM VIRUELA VIRUSES OR DAMAGED VIRUS VIRUSES, NOT IMMUNOGENS, AS A MEDICINAL PRODUCT.

Also Published As

Publication number Publication date
DE10122233A1 (en) 2002-01-24
ES2332355T3 (en) 2010-02-03
BR0112411A (en) 2003-05-27
BRPI0112411B8 (en) 2021-05-25
CN101444539A (en) 2009-06-03
DE50115181D1 (en) 2009-11-26
PE20020218A1 (en) 2002-05-19
JP2012214492A (en) 2012-11-08
DOP2001000210A (en) 2002-12-15
ZA200300276B (en) 2004-04-13
CN101444539B (en) 2016-07-06
JP2014196329A (en) 2014-10-16
DK1303302T3 (en) 2010-02-08
PT1303302E (en) 2009-11-11
KR20030019562A (en) 2003-03-06
KR100845643B1 (en) 2008-07-10
SV2002000527A (en) 2002-10-24
JP5587950B2 (en) 2014-09-10
JP5950964B2 (en) 2016-07-13
BRPI0112411B1 (en) 2018-02-27
ATE445413T1 (en) 2009-10-15

Similar Documents

Publication Publication Date Title
DK0693281T3 (en) Pharmaceutical Fluoxetine Formulations
DK1418942T3 (en) Poxvirus-containing compositions and processes for their preparation
WO2003028692A8 (en) Acne treatment using oleanolic acid
AR017404A1 (en) A COMPOSITION OF LACTOBACILOS AND USE OF THE SAME TO PREPARE A MEDICINAL PRODUCT FOR THE TREATMENT OF VAGINAL INFECTIONS.
PH12019502874A1 (en) Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments
HUP0200152A2 (en) Utilization of inhibitors of the kqt1 channel in order to produce a medicament for treating diseases which are caused by parasitic helminths and ectoparasites
ECSP034420A (en) USE OF PARAPOXVIRUS OVIS VAPES AGAINST ORGAN FIBROSIS
ES2023848B3 (en) AGENTS TO REVITALIZE, STIMULATE AND STRENGTHEN HAIR GROWTH.
CA2504872A1 (en) Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections
WO2020170033A8 (en) Method for treatment of moderate to severe erythema symptoms in rosacea patients
NO20052960L (en) Use of docosahexaenoic acid as an active substance for the treatment of lipodystrophy
TR200200724T2 (en) Use of fatty acid / amino acid soaps to increase the antimicrobial effect of pharmaceutical compositions that can be applied to the skin
EP1038529A3 (en) Agent for increasing chemokine production
WO2022169336A3 (en) Pharmaceutical composition for prevention or treatment of fibrosis comprising leuconostoc citreum strain as active ingredient
RU94025418A (en) Vitamin remedy
Baishya Topical ketoconazole therapy in a recalcitrant case of seborrhoeic dermatitis
ES2130069B1 (en) PHARMACEUTICAL PREPARATION WITH DELAYED RELEASE OF THE ACTIVE PRODUCT.
BRPI0705224A2 (en) use of pau ferro extract (caesalpinia ferrea mart.) in cosmetic and pharmaceutical formulations as a depigmenting / skin whitening agent
Nakashima et al. Mothproofing efficacy of wool-yarn treated with several kinds of medical herb against to cloth moth, Tinea Pellionella (L.)
CN109419811A (en) A kind of pharmaceutical formulation for treating onychomycosis
AR056482A1 (en) DEPIGMENTING COMPOSITION OF THE SKIN THAT INCLUDES ADAPALENE, AT LEAST A DEPIGMENTING AGENT AND, AT LEAST, AN ANTI-INFLAMMATORY AGENT
GEU2001773Y (en) Medicinal Means of Antioxidant Activity
AP2001002323A0 (en) The use of aqueous herbal preparation, pmz10, as an alternative remedy in the treatment of HIV/AIDS.
HN2001000153A (en) USE OF PARAFOXVIRUS OVIS STRAINS AGAINST ORGAN FIBROSIS. APPLICANT: BAYER AKTIENGESELLSCHAFT COUNTRY: LEVERKUSEN, GERMANY
TR200000052A2 (en) Dermatological preparation.